Navigation Links
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Date:8/3/2009

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC).

As of the time of data analysis in April 2009, 10 of the 16 studied patients were alive without evidence of disease progression, of whom eight continued to receive therapy with Stimuvax after 6.3 to 8.2 years. The remaining two living patients discontinued Stimuvax therapy after 2.4 and 5.8 years, respectively, and were without evidence of disease progression. Nine of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a complete response to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are deceased.

Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection-site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

The Phase 2b trial of Stimuvax in patients with stage IIIb/IV NSCLC was conducted by Oncothyreon, with patient enrollment concluding in 2003. Long-term follow-up of these patients was conducted by Merck KGaA of Darmstadt,
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
2. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
3. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon announces closing of $11.1 million registered direct financing
5. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Oncothyreon reports first quarter 2009 financial results
9. Oncothyreon regains compliance with NASDAQ listing requirements
10. Oncothyreon to present at Invest Northwest 2009
11. Oncothyreon reports full year and fourth quarter 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... MENLO PARK, Calif. , Feb. 26, 2015 /PRNewswire/ ... has released the latest version of the Governance ... organizations accomplish governance, risk and compliance (GRC) tasks across ... has also been updated to help customers better align ... Organizations of the Treadway Commission ) requirements. In response ...
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... an online demonstration to support life extension technologies and ... 8pm UTC, Universal Coordinated Time, on March 21st 2015, ... the world. , Eric Schulke, Founder of MILE, ... must act with urgency. The Movement for Indefinite Life ...
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
(Date:2/26/2015)... , Feb. 26, 2015 BioEnterprise today ... companies have attracted more than $2 billion in growth ... local and national investors, strategic sources, state – including ... half of the $2 billion has been raised in ... comes on the heels of the BioEnterprise Midwest ...
Breaking Biology Technology:Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... international research team has developed a mathematical and cartographical model ... in the aftermath of forest fires. In order to carry ... Environmental Modelling & Software , the authors studied a Special ... "We have developed a model that shows on maps ...
... SAN CARLOS, Calif., July 31 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2009 on Tuesday, August 4, 2009, ... chief executive officer, will host a conference call to review the ... (PT). , , The press release and ...
... ANNAPOLIS, Md., July 31 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that, effective July 28, ... unsecured senior convertible notes ("Notes") and common stock purchase warrants ... , In connection with the private placement, ...
Cached Biology Technology:Model predicts evolution of Mediterranean landscape following fires 2Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets 2PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... MBL, WOODS HOLE, MA-- Squid,s colorful, changeable skin ... octopus--to display extraordinary camouflage, the speed and diversity ... But how squid control their skin,s iridescence, ... animal,s sparkly rainbow of color, has been unknown. ...
... , This release is available in German ... three dimensional objects on a micrometer scale. But how can ... precision? Scientists at the Vienna University of Technology developed ... When biological tissue is grown, this method can allow the ...
... at the California Institute of Technology (Caltech) have made ... of individual molecules one at a time. ... doctors diagnose diseases, enable biologists to study viruses and ... scientists to better measure nanoparticles and air pollution. ...
Cached Biology News:MBL scientists discover nerves control iridescence in squid’s remarkable 'electric skin' 2The laser beam as a '3-D painter' 2Weighing molecules 1 at a time 2Weighing molecules 1 at a time 3Weighing molecules 1 at a time 4
... For nucleofection of optimized cell lines in ... the nucleofection parameters. Nucleofector Kits are only ... Different cell lines can be transfected with ... are given in brackets in percent (Efficiency ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
B-FABP (FL-132)...
... a highly purified preparation of the catalytic ... which recognizes the identical cleavage site as ... enzymatic activity (1). Novagen&'s enzyme is produced ... the highest activity available, and is qualified ...
Biology Products: